Last reviewed · How we verify
Median Dose VC004 Capsules — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Median Dose VC004 Capsules (Median Dose VC004 Capsules) — Jiangsu vcare pharmaceutical technology co., LTD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Median Dose VC004 Capsules TARGET | Median Dose VC004 Capsules | Jiangsu vcare pharmaceutical technology co., LTD | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Median Dose VC004 Capsules CI watch — RSS
- Median Dose VC004 Capsules CI watch — Atom
- Median Dose VC004 Capsules CI watch — JSON
- Median Dose VC004 Capsules alone — RSS
Cite this brief
Drug Landscape (2026). Median Dose VC004 Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/median-dose-vc004-capsules. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab